Manufacturing, vectors, applications & regulatory aspects
The last years were very promising for gene therapeutic approaches. A number of successful treatments of cancer or rare diseases were reported, as well as FDA approval of first gene therapeutic products. Until now, these pioneering treatments have been used primarily when conventional therapies reach their limits. Development, manufacturing, quality control and clinical application of gene therapeutic products are very challenging – and still far from routine.
The conference addresses the major issues on the way to save and successful products: “Gene Therapy – Ready for the Market?”
Manufacturing and quality control of gene therapeutic products
Genome editing for gene therapy development
Development and manufacturing of gene transfer vectors
Manufacturing of cell-based gene therapeutic products
Viral vectors for vaccination
Clinical applications of gene therapeutic products
Regulatory pathways to enable gene therapy
We are proud to announce renowned international Keynote Speakers.
You are most welcome to contribute to the conference programme and submit your last-minute posters until 10 December 2018.
The conference is an initiative of the DECHEMA working groups Cell Culture Technology and Medical Biotechnology.
Image source: Gernot Krautberger - stock.adobe.com